About Gordon Chen

This author has not yet filled in any details.
So far Gordon Chen has created 8 blog entries.

Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology

Tokyo, October 19, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today announced that Astellas Institute for Regenerative Medicine (“AIRM”) and Universal Cells have entered into an exclusive worldwide license agreement to research, develop and commercialize a novel cell therapy for [...]

By | October 20th, 2017|Uncategorized|0 Comments

Cell and Gene Therapy Catapult Licenses iPSC Line to Universal Cells to assist in the Development of Universal Donor Cell Line

Universal Cells to utilise CGT Catapult’s induced Pluripotent Stem Cells to create universally accepted cells for research and commercial use London, UK, 5 October 2017 – The Cell and Gene Therapy Catapult (CGT Catapult) today announced a non-exclusive licensing agreement to provide its clinical-grade induced Pluripotent Stem Cell (iPSC) line to Seattle based Universal Cells. [...]

By | October 5th, 2017|Uncategorized|0 Comments

BlueRock Therapeutics and Universal Cells Enter Collaboration and License Agreement to Generate Gene-Edited iPS Cell Lines

CAMBRIDGE, MA and SEATTLE, WA, October 3, 2017-BlueRock Therapeutics and Universal Cells Inc. today announced that they have entered into a collaboration and license agreement to create induced pluripotent stem (iPS) cell lines useful for the manufacture of allogeneic cellular therapies. “BlueRock is at the cutting edge of the cell therapy field and our collaboration [...]

By | October 3rd, 2017|Uncategorized|0 Comments

Universal Cells to Present at 2017 Cell & Gene Meeting on the Mesa

Seattle, WA September 18, 2017 – Universal Cells announced today that Claudia Mitchell, CEO will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California. This conference is the largest partnering meeting organized specifically for the cell and gene therapy [...]

By | September 18th, 2017|Uncategorized|0 Comments

Universal Cells’ CEO wins Leadership Award

Seattle, WA – May 30th, 2017 – Universal Cells’ CEO and Co-founder, Claudia Mitchell received the Gold award in Leadership at the Seattle’s 3rd Annual French-American Business Awards event, held on Friday, May 12, 2017 at the Rainier Club in downtown Seattle. Organized by the French-American Chamber of Commerce of the Pacific Northwest, the event’s [...]

By | May 30th, 2017|Uncategorized|0 Comments

Universal Cells’ Gene Editing Strategy Published in Nature Biotechnology

Seattle, WA – May 15th, 2017 – Universal Cells announced today that a report from Universal Cells’ CSO Dr. David Russell and researchers at the University of Washington demonstrating the potential of Universal Cells’ technology for creating universal donor stem cells has been published in the journal Nature Biotechnology. The paper’s focus is [...]

By | May 15th, 2017|Uncategorized|0 Comments

Universal Cells to present at 5th Annual Cell & Gene Therapy Investor Day, April 27th in Boston

Seattle, WA – Universal Cells announced today that Claudia Mitchell, CEO will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at 4pm EST in Boston. The following are specific details regarding Universal Cells’ presentation: Event:          Alliance for Regenerative Medicine’s Cell & [...]

By | April 20th, 2017|Uncategorized|0 Comments

Dr. Bryan Steadman to join Universal Cells Inc. as Chief Technology Officer

Seattle, WA – Universal Cells Inc. (http://www.universalcells.com) has announced that Dr. Bryan Steadman has joined the company as Chief Technology Officer.  He is responsible for the translation of R&D to GMP activities and leadership of the Quality, Regulatory, Process Development and Manufacturing Operations. “Universal Cells offers the potential to move stem cell therapy from patient [...]

By | March 1st, 2017|Uncategorized|0 Comments